Early brainstem [18F]THK5351 uptake is linked to cortical hyperexcitability in healthy aging

JCI Insight. 2021 Jan 25;6(2):e142514. doi: 10.1172/jci.insight.142514.

Abstract

BACKGROUNDNeuronal hyperexcitability characterizes the early stages of Alzheimer's disease (AD). In animals, early misfolded tau and amyloid-β (Aβ) protein accumulation - both central to AD neuropathology - promote cortical excitability and neuronal network dysfunction. In healthy humans, misfolded tau and Aβ aggregates are first detected, respectively, in the brainstem and frontomedial and temporobasal cortices, decades prior to the onset of AD cognitive symptoms. Whether cortical excitability is related to early brainstem tau - and its associated neuroinflammation - and cortical Aβ aggregations remains unknown.METHODSWe probed frontal cortex excitability, using transcranial magnetic stimulation combined with electroencephalography, in a sample of 64 healthy late-middle-aged individuals (50-69 years; 45 women and 19 men). We assessed whole-brain [18F]THK5351 PET uptake as a proxy measure of tau/neuroinflammation, and we assessed whole-brain Aβ burden with [18F]Flutemetamol or [18F]Florbetapir radiotracers.RESULTSWe found that higher [18F]THK5351 uptake in a brainstem monoaminergic compartment was associated with increased cortical excitability (r = 0.29, P = 0.02). By contrast, [18F]THK5351 PET signal in the hippocampal formation, although strongly correlated with brainstem signal in whole-brain voxel-based quantification analyses (P value corrected for family-wise error [PFWE-corrected] < 0.001), was not significantly associated with cortical excitability (r = 0.14, P = 0.25). Importantly, no significant association was found between early Aβ cortical deposits and cortical excitability (r = -0.20, P = 0.11).CONCLUSIONThese findings reveal potential brain substrates for increased cortical excitability in preclinical AD and may constitute functional in vivo correlates of early brainstem tau accumulation and neuroinflammation in humans.TRIAL REGISTRATIONEudraCT 2016-001436-35.FUNDINGF.R.S.-FNRS Belgium, Wallonie-Bruxelles International, ULiège, Fondation Simone et Pierre Clerdent, European Regional Development Fund.

Keywords: Aging; Alzheimer’s disease; Neuroimaging; Neuroscience.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / diagnostic imaging
  • Alzheimer Disease / pathology
  • Alzheimer Disease / physiopathology
  • Aminopyridines / pharmacokinetics*
  • Amyloid beta-Peptides / metabolism
  • Brain Stem / diagnostic imaging*
  • Brain Stem / metabolism*
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology*
  • Cross-Sectional Studies
  • Early Diagnosis
  • Electroencephalography
  • Female
  • Fluorine Radioisotopes / pharmacokinetics
  • Functional Neuroimaging
  • Healthy Aging / metabolism*
  • Healthy Aging / pathology
  • Healthy Aging / physiology
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Positron-Emission Tomography
  • Quinolines / pharmacokinetics*
  • Radiopharmaceuticals / pharmacokinetics*
  • Transcranial Magnetic Stimulation
  • tau Proteins / metabolism

Substances

  • Aminopyridines
  • Amyloid beta-Peptides
  • Fluorine Radioisotopes
  • MAPT protein, human
  • Quinolines
  • Radiopharmaceuticals
  • THK5351
  • tau Proteins

Associated data

  • EudraCT/2016-001436-35

Grants and funding

[18F]Flutemetamol doses were provided and cost covered by GE Healthcare Ltd (Little Chalfont, UK) as part of an investigator sponsored study (ISS290) agreement. This agreement had no influence on the protocol and results of the study reported here.